LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics today and set a price target of $46.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda’s rating is based on several promising developments within Viridian Therapeutics. The company has reported a strong financial position, ending Q2 2025 with $563.4 million in cash and investments, which is projected to sustain operations into the second half of 2027. This financial stability provides a solid foundation for the company’s ongoing and future projects.
Additionally, Viridian’s pipeline shows significant potential, particularly with veligrotug, which is on track for a Biologics License Application submission in the second half of 2025. The drug has received Breakthrough Therapy Designation from the FDA, indicating its potential for priority review due to its rapid and robust efficacy in treating thyroid eye disease (TED). Furthermore, the VRDN-003 program is progressing well, with pivotal data expected in the first half of 2026, and if positive, could lead to a BLA submission by the end of 2026. These factors collectively support the Buy rating, highlighting the company’s promising future prospects in the therapeutic market.
Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Dianthus Therapeutics, and Disc Medicine. According to TipRanks, Katkhuda has an average return of 14.6% and a 45.60% success rate on recommended stocks.